Haleon is a consumer healthcare company selling over-the-counter medicines and everyday health products. Its brands span oral health, pain relief, respiratory health, digestive health, and vitamins and supplements, including Sensodyne, Centrum, Advil, and Voltaren in relevant markets. It competes through brand distribution, product innovation, and retail and pharmacy channels rather than prescription drug development.
Haleon plc ADR (HLN) has a MarketKingdoms composite score of 60.7 (B-), an B-range rating. It ranks 1230th of 1,866 covered companies, 62nd of 78 in Healthcare (sector average 64.4) and 5th of 6 in Drug Manufacturers - Specialty & Generic. Scores as of 2026-10-26.
Its strongest lenses are KPI momentum at 84 (Healthcare average 78) and Stock selection at 82 (Healthcare average 79). Its weakest lenses are Expansion (growth) at 29 (sector average 50) and Trend (momentum) at 37 (sector average 50).
| Lens | Type | HLN | Healthcare average | Drug Manufacturers - Specialty & Generic average | Percentile in sector |
|---|---|---|---|---|---|
| Industry opportunity | Research signal | 74 | 81 | 74 | 15th |
| Stock selection | Research signal | 82 | 79 | 76 | 69th |
| KPI momentum | Research signal | 84 | 78 | 71 | 68th |
| Catalyst watch | Research signal | 73 | 74 | 71 | 41st |
| Price (valuation) | Fundamental lens | 64 | 50 | 65 | 71st |
| Expansion (growth) | Fundamental lens | 29 | 50 | 39 | 15th |
| Quality (profitability) | Fundamental lens | 62 | 50 | 63 | 69th |
| Trend (momentum) | Fundamental lens | 37 | 50 | 48 | 33rd |
The most recent call analysed was held on 2026-07-30 (fiscal 2026 Q2). MarketKingdoms checks what management promised on each call against what it later delivered.
The stock's valuation gap is +4.3%: its price is in line with the path its market, sector and industry moves explain. Factor sensitivity: market beta 0.16, sector beta 0.76, industry beta -0.02; the factor model explains 29% of its moves (R²).
| Company | Composite | Grade | Valuation gap |
|---|---|---|---|
| Ironwood Pharmaceuticals Inc. (IRWD) | 76.7 | A- | -66.6% |
| Viatris Inc. (VTRS) | 63.8 | B- | -13.1% |
| Teva Pharmaceutical Industries Ltd. ADR (TEVA) | 63.5 | B- | -29.4% |
| United Therapeutics Corp. (UTHR) | 62.7 | B- | -10.5% |
| Zoetis Inc. (ZTS) | 51.2 | C | -2.7% |
Haleon plc ADR financial statements · Healthcare sector ranking · Drug Manufacturers - Specialty & Generic industry ranking · All covered companies
The composite score (0–100, graded A+ to D-) blends research signals from each earnings call with fundamental lenses from SEC filings and market prices. Research signals: Industry opportunity, Stock selection, KPI momentum and Catalyst watch, read from what management said and whether it delivered. Fundamental lenses: Price (valuation), Expansion (growth), Quality (profitability) and Trend (momentum). Scores are recalculated every night and after every earnings call. The valuation gap compares the actual price path with the path the stock's market, sector and industry moves explain; it is a model comparison, not a fair-value estimate.
General information, not investment advice.